EXACT Sciences Co. (NASDAQ:EXAS) Director Katherine S. Zanotti Sells 1,164 Shares of Stock
EXACT Sciences Co. (NASDAQ:EXAS) Director Katherine S. Zanotti sold 1,164 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $96.13, for a total value of $111,895.32. Following the transaction, the director now directly owns 41,907 shares of the company’s stock, valued at approximately $4,028,519.91. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
EXAS opened at $97.90 on Friday. EXACT Sciences Co. has a 12 month low of $35.25 and a 12 month high of $123.31. The stock has a 50-day moving average of $90.42 and a 200 day moving average of $81.98. The company has a current ratio of 6.09, a quick ratio of 5.81 and a debt-to-equity ratio of 0.64.
EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Wednesday, May 6th. The medical research company reported ($0.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.12). EXACT Sciences had a negative net margin of 10.04% and a negative return on equity of 13.98%. The business had revenue of $347.80 million for the quarter, compared to analysts’ expectations of $347.47 million. During the same quarter last year, the firm earned ($0.66) EPS. The firm’s quarterly revenue was up 114.7% on a year-over-year basis. On average, analysts expect that EXACT Sciences Co. will post -1.63 earnings per share for the current year.
Several research analysts have recently issued reports on EXAS shares. Oppenheimer reissued a “buy” rating on shares of EXACT Sciences in a research report on Wednesday, July 8th. Evercore ISI started coverage on EXACT Sciences in a research report on Thursday, April 2nd. They issued an “outperform” rating and a $70.00 target price for the company. Canaccord Genuity decreased their target price on EXACT Sciences from $120.00 to $110.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Citigroup increased their target price on EXACT Sciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, June 25th. Finally, BidaskClub raised EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Friday, July 17th. Eighteen research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $104.80.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Further Reading: Economic Reports
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.